| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 1940.5 | 1909.9 | 1403.8 |
| Other income | 3.0 | 4.0 | 5.8 |
| Total income | 1943.5 | 1913.9 | 1409.6 |
| Profit before exceptional items & tax | 67.1 | 57.9 | 36.4 |
| Profit before tax | 67.1 | 57.9 | 36.4 |
| Net profit | 52.1 | 45.1 | 30.2 |
| Operating margin | 3.5% | 3.0% | 2.6% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +72.50% |
|---|---|
| Net profit, quarter on quarter | +15.50% |
| Revenue, year on year | +38.20% |
| Operating profit, year on year | +109.50% |
| Operating profit, quarter on quarter | +18.90% |
BSE results filing, NSE: ENTERO. Figures extracted from the filing.
Entero Healthcare Solutions Ltd: key numbers
- Share price
- ₹1,821.80
- Market cap
- ₹7,929 Cr
- Revenue (annual)
- ₹6,591 Cr
- Net profit (annual)
- ₹115.0 Cr
- P/E (TTM)
- 63.2×Sector 57.8×
- Promoter holding
- 52.40%-0.02% QoQ
- FII holding
- 4.36%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Entero Healthcare Solutions Ltd
All →Entero Healthcare Solutions Capital Structure Change
Surbhi Singh (Prasid Uno Family Trust), a non-promoter, sold 21.30 lakh Entero Healthcare shares via bulk/block deals. Stake fell from 7.94% to 3.05%; no transaction value disclosed.
Entero Healthcare Solutions Legal & Regulatory
Entero Healthcare Solutions reported a GST penalty of Rs. 0.13 Crore imposed on its subsidiary, ACE Cardiopathy Solutions, for non-generation of an E-Invoice.
- Value
- ₹0.13 Cr
Entero Healthcare Solutions Other Announcement
Entero Healthcare Solutions Ltd filed its quarterly shareholding pattern for the period ended March 31, 2026, as per regulatory requirements.
Entero Healthcare Solutions Earnings Call Transcript: Key Takeaways
Entero delivered a strong Q1 FY27 with 38.2% revenue growth and hit its full-year EBITDA margin target of 5% in the first quarter itself, signaling rapid structural margin expansion.
- Call
- Guides 23% growth
Entero Healthcare Solutions Investor Presentation: Key Takeaways
Q1FY27 revenue grew 38.2% YoY to ₹1,940.5 Cr with significant margin expansion. Strategy focuses on MedTech scaling and consolidating India's fragmented pharmaceutical distribution market.
Entero Healthcare Solutions Earnings Call: Key Takeaways
Entero delivered solid FY26 results, meeting all guidance parameters. Management transitions focus toward organic growth and margin expansion through technology-led scaling and higher-margin MedTech distribution.